Gyre Therapeutics Inc (GYRE)

Currency in USD
7.9300
+0.2500(+3.26%)
Closed·
7.93000.0000(0.00%)
·
GYRE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.52978.0000
52 wk Range
6.110013.7500
Key Statistics
Prev. Close
7.68
Open
7.62
Day's Range
7.5297-8
52 wk Range
6.11-13.75
Volume
74.74K
Average Volume (3m)
73.3K
1-Year Change
-27.5799%
Book Value / Share
1.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GYRE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.0000
Upside
+126.99%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Gyre Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Gyre Therapeutics Inc Company Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Compare GYRE to Peers and Sector

Metrics to compare
GYRE
Peers
Sector
Relationship
P/E Ratio
109.0x−5.9x−0.6x
PEG Ratio
1.020.010.00
Price/Book
7.1x2.3x2.6x
Price / LTM Sales
6.8x9.4x3.4x
Upside (Analyst Target)
134.4%104.6%41.5%
Fair Value Upside
Unlock5.2%5.5%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.0000
(+126.99% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy18.00+126.99%-MaintainOct 16, 2025
Jefferies
Buy16.00+101.77%-New CoverageOct 10, 2025
H.C. Wainwright
Buy18.00+126.99%-New CoverageAug 26, 2025
Noble Capital
Buy---New CoverageMar 11, 2025

Earnings

Latest Release
Nov 07, 2025
EPS / Forecast
0.03 / 0.05
Revenue / Forecast
30.56M / 33.55M
EPS Revisions
Last 90 days

GYRE Income Statement

People Also Watch

6.870
CRMD
+1.33%
6.50
IBRX
+17.75%
56.31
BMRN
+3.15%
128.68
KTOS
-1.56%
22.63
RARE
+0.62%

FAQ

What Is the Gyre Therapeutics (GYRE) Stock Price Today?

The Gyre Therapeutics stock price today is 7.9300

What Stock Exchange Does Gyre Therapeutics Trade On?

Gyre Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Gyre Therapeutics?

The stock symbol for Gyre Therapeutics is "GYRE."

What Is the Gyre Therapeutics Market Cap?

As of today, Gyre Therapeutics market cap is 719.85M.

What Is Gyre Therapeutics's Earnings Per Share (TTM)?

The Gyre Therapeutics EPS (TTM) is 0.04.

When Is the Next Gyre Therapeutics Earnings Date?

Gyre Therapeutics will release its next earnings report on Mar 30, 2026.

From a Technical Analysis Perspective, Is GYRE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Gyre Therapeutics Stock Split?

Gyre Therapeutics has split 3 times.

How Many Employees Does Gyre Therapeutics Have?

Gyre Therapeutics has 579 employees.

What is the current trading status of Gyre Therapeutics (GYRE)?

As of Jan 20, 2026, Gyre Therapeutics (GYRE) is trading at a price of 7.9300, with a previous close of 7.6800. The stock has fluctuated within a day range of 7.5297 to 8.0000, while its 52-week range spans from 6.1100 to 13.7500.

What Is Gyre Therapeutics (GYRE) Price Target According to Analysts?

The average 12-month price target for Gyre Therapeutics is USD18.0000, with a high estimate of USD20 and a low estimate of USD16. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +126.99% Upside potential.

What Is the GYRE Premarket Price?

GYRE's last pre-market stock price is 7.8300. The pre-market share volume is 200.0000, and the stock has decreased by 0.1500, or 1.9500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.